Monreal-Feil, MediaRelations, of IBM North America, 1-954-453-9490, . HOUSTON, Jan 15 /PRNewswire-FirstCall/ ICO, Inc. ICO's Bayshore Industrial subsidiary produces specialty compounds,concentrates and additives primarily for the plastic film industry Additional information about ICO, Inc. can be found on the Company's websiteat SOURCEICO, Inc.Brad Leuschner of ICO, Inc., 1-713-351-4100. GQ Announces the Second Annual 'Best New Menswear Designers in America'Contest in Conjunction With the CFDAThe Levi's(R) Brand and Bloomingdale's Are Participating PartnersNEW YORK, Jan. The winner will take part in a mentoring program led by GQ, the Levi's brand,and Bloomingdale's. A select item or outfit from the winning designer'scollection for Levi's will be featured in the September 2009 issue of GQ."The Levi's brand has a long history of supporting emerging American designtalent," added Steve Evans, vice president of merchandising for the Levi'sbrand."After all, it was the pioneering, innovative spirit of Levi Straussthat led to the invention of an American fashion icon - the original,button-fly 501 jean.We're excited to continue in this tradition bypartnering with GQ and Bloomingdale's to celebrate the innovation of a newgeneration of American menswear designers."The panel of industry experts who will select the 2009 winner consists of:Thom Browne, American menswear designer; Steve Evans, the Levi's brand vicepresident of merchandising; Kevin Harter, Bloomingdale's vice president offashion direction; Steven Kolb, CFDA executive director; Jim Moore, GQcreative director; and Jim Nelson, GQ editor-in-chief.The final selectionwill be made by consensus at a meeting of the selection panel that will takeplace in February 2009.About the CFDAThe Council of Fashion Designers of America, Inc.
The magazine is published by Conde Nast Publications.SOURCEGQDan Scheffey, GQ, 1-212-286-4622, or Darryl Brantley, GQ, 1-212-286-8549. HOUSTON, Jan 15 /PRNewswire-FirstCall/ Landry's Restaurants, Inc. (NYSE:LNY) today announced that it intends to commence an offering of senior notesdue 2011 for gross proceeds of $270 million.The notes will be secured andguaranteed by certain of Landry's subsidiaries.The notes will be offered toqualified institutional buyers pursuant to Rule 144A under the Securities Actof 1933, as amended (the "Securities Act"), outside the United States pursuantto Regulation S under the Securities Act and to a limited number ofinstitutional accredited investors under Regulation D promulgated under theSecurities Act.The Company plans to use the net proceeds of the offering along with funds tobe received from an amended and restated bank credit facility that itannounced today, to refinance its outstanding debt, pay related transactionfees and expenses and for general corporate purposes.The securities have not been registered under the Securities Act or any statesecurities laws and may not be offered or sold in the United States absentregistration or an applicable exemption from the registration requirements ofthe Securities Act and applicable state laws.This press release shall not constitute an offer to sell or a solicitation ofan offer to purchase any of these securities, and shall not constitute anoffer, solicitation or sale in any state or jurisdiction in which such anoffer, solicitation or sale would be unlawful.This press release is beingissued pursuant to and in accordance with Rule 135c under the Securities Act.The Company is a national, diversified restaurant, hospitality andentertainment company principally engaged in the ownership and operation offull-service, casual dining restaurants, primarily under the names ofRainforest Cafe, Saltgrass Steak House, Landry's Seafood House, Charley'sCrab, The Chart House, and the Signature Group of restaurants.The Company isalso engaged in the ownership and operation of select hospitality businesses,including the Golden Nugget Hotel & Casino in Las Vegas and Laughlin, Nevada.This press release contains certain forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section 21E of theSecurities Exchange Act of 1934, as amended, which are intended to be coveredby safe harbors created thereby.Readers are cautioned that allforward-looking statements are based largely on the Company's expectations andinvolve risks and uncertainties, some of which cannot be predicted or arebeyond the Company's control. Some factors that could realistically causeresults to differ materially from those projected in the forward-lookingstatements include the occurrence of any event, change or other circumstancesthat could give rise to the Company's inability to consummate the notesoffering and the amendment and restatement of its bank credit facility or toobtain alternative financing to pay off its existing debt; the effects oflocal and national economic, credit and capital market conditions on theeconomy in general, and on the gaming, restaurant and hotel industries inparticular; changes in laws, including increased tax rates, regulations oraccounting standards, third-party relations and approvals, and decisions ofcourts, regulators and governmental bodies; litigation outcomes and judicialactions; acts of war or terrorist incidents or natural disasters; the effectsof competition, including locations of competitors and operating and marketcompetition; ineffective marketing or promotions, weather, managementturnover, higher interest rates and gas prices, construction at the GoldenNugget properties, negative same store sales and other risks described in thefilings of the Company with the Securities and Exchange Commission, includingbut not limited to, the Company's Annual Report on Form 10-K for the yearended December 31, 2007.The Company may not update or revise anyforward-looking statements made in this press release SOURCELandry's Restaurants, Inc.Steven L. Scheinthal, Executive Vice President and General Counsel, or Rick H.Liem, Executive Vice President and CFO, both of Landry's Restaurants, Inc.,1-713-850-1010. Healthy Vessel Seen in 6-Month Follow-up Exam on First Patient to ReceivePreventive Treatment for Vulnerable Plaque ROTTERDAM, Netherlands and DOYLESTOWN, Pa., Jan.
15 /PRNewswire/ The firstpatient receiving focal preventive treatment for vulnerable plaque recentlyunderwent a 6-month follow-up examination that revealed successfulstabilization of the target plaque. Serruys, MD, PhD, of Erasmus University, placed avProtect(TM) Luminal Shield in the left anterior descending (LAD) coronaryartery of the patient at Erasmus Medical Center in Rotterdam in June of 2008.The 64-year-old man is enrolled in SECRITT I, a pilot study designed toevaluate the vProtect(TM) Luminal Shield as a treatment for vulnerableplaques"silent" atherosclerotic deposits in the coronary arteries that donot produce symptoms until they rupture with potentially fatal consequences. To date, the treated artery demonstrated excellent blood flow and healing.Aspart of the healing process the Shield is now covered by a thin layer oftissue, incorporating it into the arterial wall. This is a hallmark of asuccessful implant and demonstrated that the Shield performed much better thanwould be expected for traditional bare metal stents and comparable to thefirst generation of drug-eluting stents."The self-expanding vProtect(TM) Luminal Shield minimizes injury on deploymentenabling safe placement over rupture-prone vulnerable plaques," said PatriciaScheller, CEO of Prescient Medical, the manufacturer of the vProtect(TM)Luminal Shield.
Using a combination of ultrasound andoptical imaging techniques, the SECRITT I investigators examine the coronaryarteries for signs of additional, non-flow-limiting vulnerable plaques, forwhich patients would not generally receive treatment. Patients with vulnerableplaques undergo follow-up diagnostic catheterizations 6 months post-treatment,at which time investigators determine the Shield's impact. According to Professor Serruys, the vProtect(TM) Luminal Shield represents alogical extension of modern cardiac medicine: "We are very good at openingarteries that are blocked, but we have not succeeded in preventing heartattacks related to plaque rupture. The vProtect(TM) Luminal Shield hasdemonstrated that it can be safely placed over a vulnerable lesion withoutrupturing the plaque, and the results at six months are extremely promising.The Shield performed exactly as intended, allowing us to prevent plaquerupture and an acute event, rather than trying to repair the damage after thefact." About Prescient Medical, Inc.Prescient Medical, Inc.